Close Menu

NEW YORK (GenomeWeb) — DNA testing firm PathogenDx announced today that it has closed a $3.4 million convertible note round.

The round was co-led by Altitude Investment Management and the Panther Opportunity Fund, with participation from CanopyVentures, Tendaji Investments, PB Venture Group, Salveo Capital, Halley Valley Venture, FlatIron Group, and Spearflower VC. Specific terms of the round were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.